(Shi Mengzhu, a reporter from the Peoples Daily Health Client) from November 5th to 10th, the 7th Expo was held in Shanghai.According to information on the official website of the Expo, a total of 3,496 exhibitors from 129 countries and regions participated in this exhibition.During the 7th Expo, a reporter from the Peoples Daily Health Client talked to members of the Presidium (RDPAC) Presidium of the Chinese Foreign Investment Enterprise Association (RDPAC) of the China Foreign Investment Enterprise Association, listening to the Expo in their eyes.
Vice Chairman of the Executive Committee of the RDPAC, Nuo and Nords Global Senior Vice President and President of the Greater China, Zhou Xiaping (left), chairman of the RDPAC Executive CommitteeJean-Christophe Pointeau (middle), vice chairman of the RDPAC Executive Committee, Senior Vice President of Takeda Pharmaceuticals, and Shan Guohong (right)
Entry Expo in the eyes of "Old Friends"Chairman of the Executive Committee of the RDPAC, President Pfizer China, Jean-Christophe Pointeau said that at the Expo this year, PfizerThe announcement was issued again, and four global innovation products and treatment plans were exhibited for the first time, covering the field of tumor therapy, the field of hemophilia and antibiotic treatment."This is an important window for observing Chinas promise of opening up to the outside world. The continuous successful holding of the Expo shows that China is unswervingly committed to high -level interaction with the global economy." He said, "We also want to borrow this Expo.One platform conducts meaningful communication, explores new ways to innovate and grow.Zhou Xiaping, Vice Chairman of the RDPAC Executive Committee, Nuo and Nords Global Senior Vice President and President of Greater China, told the Peoples Daily Health Client reporter that this is not only the "grand event at the doorstep", but also a vast platform for transnational enterprises to share China.EssenceNuo and Nords many global innovative products have achieved Chinas first exhibition in the Expo.These "Baby Kaibao" walked into the "big market" from the "four -leaf grass" to benefit the majority of patients.
"This year is the 30th anniversary of Takedas development in China. Takeda and the Expo accompanied them to grow side by side. With each years Expo, Takeda in the Chinese market in the Chinese marketThe strategic development is also constantly upgrading.The continuous successful holding of the Expo has fully demonstrated Chinas determination to firmly expand and share development opportunities.
Actively participate in the innovation and upgrade of the Chinese pharmaceutical industry
Pfizer has witnessed the rapid development of the Chinese market and the continuous improvement of the business environment.In the past, innovative drugs usually listed in China 5 to 10 years later than Europe and the United States.Some drugs are now approved almost or even earlier at the same time.
Single Guohong told reporters from the Health Client of the Peoples Daily that in recent years, my countrys efforts and achievements in rare disease drug protection policies are obvious to all.As a multinational pharmaceutical company, Takeda China is deeply honored to be able to participate. The prevention and control of rare diseases is a systematic project that requires the strength of the whole society to work together.It can be seen that the current country is also building a full -chain model of "early discovery, early diagnosis, early treatment, management, medicinal, and affordable", and strives not to allow a rare disease patient to "lose".
In the past 25 years, RDPAC members have introduced more than 800 innovative drugs to China.Zhou Xiaping said that since 2017, 161 innovative drugs have been included in the national medical insurance and drug catalogs in RDPAC members. Each company is very willing to actively participate in the innovation and upgrading of the Chinese pharmaceutical industry to jointly build a sustainable pharmaceutical innovation ecosystem to share Chinas development.opportunity.
